SG11201408428PA - Dosage regime of fusion compounds - Google Patents

Dosage regime of fusion compounds

Info

Publication number
SG11201408428PA
SG11201408428PA SG11201408428PA SG11201408428PA SG11201408428PA SG 11201408428P A SG11201408428P A SG 11201408428PA SG 11201408428P A SG11201408428P A SG 11201408428PA SG 11201408428P A SG11201408428P A SG 11201408428PA SG 11201408428P A SG11201408428P A SG 11201408428PA
Authority
SG
Singapore
Prior art keywords
international
llll
iii
rule
peptide
Prior art date
Application number
SG11201408428PA
Inventor
Shamala Devi K C Sekaran
Hussin A Rothan
Eng Huan Ung
Bakar Ag Muhammad Sagaf Abu
Original Assignee
Biovalence Sdn Bhd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovalence Sdn Bhd filed Critical Biovalence Sdn Bhd
Publication of SG11201408428PA publication Critical patent/SG11201408428PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2497—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
    • C12Y302/02021—DNA-3-methyladenine glycosylase II (3.2.2.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
    • C12Y302/02022—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2) rRNA N-glycosylase (3.2.2.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 January 2014 (03.01.2014) WIPOIPCT (10) International Publication Number WO 2014/003536 Al (51) International Patent Classification: C07K19/00 (2006.01) A61P 31/00 (2006.01) A61K38/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/MY2013/000114 (22) International Filing Date: 25 June 2013 (25.06.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PI 2012002923 26 June 2012 (26.06.2012) MY (71) Applicant: BIOVALENCE SDN. BHD. [MY/MY]; 21, Jalan SS25/34, Taman Mayang Industrial Park, Petaling Jaya 47301 (MY). (72) Inventors: SEKARAN, Shamala Devi K C; 17 Jin 10/10 F, Petaling Jaya 46000 (MY). ROTHAN, Hussin A.; 3-7- 7 OUG Condominium, Jin 3A/155, Kuala Lumpur 58000 (MY). UNG, Eng Huan; No. 2, Lorong Ujana Kingfisher 9, Kingfisher Ujana 88450, Kota Kinabalu, Sabah (MY). ABU BAKAR, Ag. Muhammad Sagaf; P.O. Box 81, Pos Mini, Central Plaza, 88300 Kota Kinabalu, Sabah (MY). (74) Agents: JEFFREY, Fiona Teresa et al.; Marks & Clerk (Malaysia) SDN BHD, PO Box 11182, 50738 Kuala Lum­ pur (MY). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). [Continued on next page] (54) Title: DOSAGE REGIME OF FUSION COMPOUNDS m m o o i i 61 ATGGCCATGGGGCGTATTTGCCGTTGCATTTGCGGCCGTGGCATTTGCCGCTGCATCTGT 21 121 41 181 61 241 81 301 101 361 121 421 141 481 TATACCGGCAACTATGAAAACCTGCAGACCGCGGCGCATAAAATTCGTGAAAACATCGAT 161 541 181 601 201 661 221 721 241 781 261 841 281 901 301 961 321 1021 341 1001 361 ATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGCG MKYLLPTAAAGLLLLAAQPA MAMGRICRCICGRGICRCIC GGCGTGCCGGGTGTTGGTGTTCCGGGTGTGGGTGGTGCGACCGGATCCGATGTGAACTTT V G V V V D N GATCTGAGCACCGCGACCGCGAAAACCTATACCAAATTCATCGAAGATTTTCGTGCGACC DLSTATAKTYTKFIEDFRAT CTGCCGTTTAGCCATAAAGTGTATGATATCCCGCTGCTGTATAGCACCATTAGCGATAGC LPFSHKVYDI PLLYSTISDS CGTCGTTTTATTCTGCTGGATCTGACCAGCTATGCGTATGAAACCATTAGCGTGGCGATT RRFILLD.LTSYAYETISVAI GATGTGACCAACGTGTATGTGGTGGCGTATCGTACCCGTGATGTGAGCTACTTTTTCAAA DVTNVYVVAYRTRDVSYFFK GAAAGCCCGCCGGAAGCGTACAACATTCTGTTTAAAGGCACCCGTAAAATTACCCTGCCG N K K YTGNYENLQTAAHKIRENID CTGGGCCTGCCGGCCCTGAGCAGCGCGATTACCACCCTGTTTTATTATAACGCGCAGAGC LGLPALSSAITTLFYYNAQS GCGCCGAGCGCGCTGCTGGTGCTGATTCAGACCACCGCGGAAGCGGCGCGTTTTAAATAT APSALLVLIQTTAEAARFKY ATTGAACGCCACGTGGCGAAATATGTGGCGACCAACTTTAAACCGAACCTGGCCATTATT H V A K V N K N AGCCTGGAAAACCAGTGGAGCGCCCTGAGCAAACAAATTTTTCTGGCCCAGAACCAGGGC SLENQWSALSKQIFLAQNQG GGCAAATTTCGTAATCCGGTGGATCTGATTAAACCGACCGGCGAACGTTTTCAGGTGACC GKFRN PVDL 1 KPTGERFQVT AATGTGGATAGCGATGTGGTGAAAGGCAACATTAAACTGCTGCTGAACAGCCGTGCGAGC N V N N ACCGCGGATGAAAACTTTATTACCACCATGACCCTGCTGGGCGAAAGCGTGGTGGAATTC TADENFITTMTLLGESVVEF CCGTGGGCGCTGTGGAAAACCATGCTGAAAGAACTGGGCACGATGGCGCTGCATGCGGGT W W M K M H AAAGCGGCGCTGGGTGCGGCAGCGGATACCATTAGCCAGGGCACCCAGGTTCCGGGCGTG KAALGAAADT I SQGTQVPGV GGCGTTCCGGGCGTTGGTAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGA GVPGVGKLAAALEHHHHHH* (57) Abstract: Use of at least one fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, poly­ peptide B; and at least one polypeptide A which is antimi­ a crobial peptide and/or at least one Cationic AntiMicrobial Peptide, polypeptide C for the preparation of a medicament for treating a cancer and/or microbial infection wherein a the medicament is suitable for oral administration pre food in­ take. O CJ o & WO 2014/003536 Al III llll IIII III III Hill III III III Hill II llll llll 111 111 mill llll 111 llll Declarations under Rule 4.17: Published: — ofinventorship (Rule 4.17(iv)) — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
SG11201408428PA 2012-06-26 2013-06-25 Dosage regime of fusion compounds SG11201408428PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MYPI2012002923 2012-06-26
PCT/MY2013/000114 WO2014003536A1 (en) 2012-06-26 2013-06-25 Dosage regime of fusion compounds

Publications (1)

Publication Number Publication Date
SG11201408428PA true SG11201408428PA (en) 2015-01-29

Family

ID=49783569

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408428PA SG11201408428PA (en) 2012-06-26 2013-06-25 Dosage regime of fusion compounds

Country Status (7)

Country Link
US (1) US20150284438A1 (en)
EP (1) EP2864361A4 (en)
AU (1) AU2013281395A1 (en)
CA (1) CA2877272A1 (en)
PH (1) PH12014502832A1 (en)
SG (1) SG11201408428PA (en)
WO (1) WO2014003536A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109667A1 (en) 2016-12-15 2018-06-21 Nestec Sa Compositions and methods that modulate white blood cells or neutrophils in a companion animal
CN107056947B (en) * 2016-12-23 2021-04-20 中国人民解放军第四军医大学 anti-HBV replication targeted fusion protein and construction method thereof
CN106967740B (en) * 2017-02-17 2020-11-13 芜湖天明生物技术有限公司 Escherichia coli fusion expression plectasin, preparation method and application thereof
CN108324924A (en) * 2018-04-23 2018-07-27 海南海泽惠生物科技有限公司 Application of the bitter melon protein in preparing anti-nipple tumor virus infection drug
CN109266655B (en) * 2018-09-06 2021-11-09 浙江大学 Antibacterial peptide and prokaryotic expression method and application thereof
CN108904794A (en) * 2018-09-29 2018-11-30 商丘美兰生物工程有限公司 The immunization method of live vaccines of hog cholera
US10987390B2 (en) * 2018-12-06 2021-04-27 Maryam Rahimi Plant stem cell product treatments
CN112778403B (en) * 2021-01-04 2022-08-19 上海大学 Cyclic peptide antitumor active compound and preparation method and application thereof
CN112806378B (en) * 2021-01-12 2021-08-13 厦门大学 Disinfectant composition for preventing coronavirus
US20240108702A1 (en) * 2021-01-20 2024-04-04 The University Of Southern California Use Of Naturally Occurring Cyclic Peptides For Treatment Of SARS-COV-2 Infection
CN112707952B (en) * 2021-02-22 2022-04-08 青岛森盛生物医药科技有限公司 Antimicrobial peptide from branchiostoma belcheri
CN113801198B (en) * 2021-08-04 2023-06-27 江苏尚宝牧业有限公司 Hybrid antibacterial peptide and preparation method and application thereof
CN114107392A (en) * 2021-11-22 2022-03-01 昆明理工大学 Preparation method of CVB5 virus-like particles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
CA2162689C (en) * 1993-05-12 2000-07-18 Marc D. Better Immunotoxins comprising gelonin and an antibody
US5597569A (en) * 1993-10-25 1997-01-28 Bristol-Myers Squibb Company Bryodin 2 a ribosome-inactivating protein isolated from the plant Bryonia dioica
CN101434657B (en) * 2008-12-03 2011-09-07 山西康宝生物制品股份有限公司 Preparation and use of recombinant mtVEGF121/MAP30KDEL fusion noxioussubstance
CN103429621B (en) * 2011-01-07 2017-08-01 威联生物制药私人有限公司 Antimicrobial fusion compound and application thereof

Also Published As

Publication number Publication date
EP2864361A4 (en) 2016-06-01
PH12014502832A1 (en) 2015-02-02
WO2014003536A8 (en) 2015-02-05
CA2877272A1 (en) 2014-01-03
WO2014003536A1 (en) 2014-01-03
WO2014003536A9 (en) 2014-01-30
EP2864361A1 (en) 2015-04-29
US20150284438A1 (en) 2015-10-08
AU2013281395A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
SG11201408428PA (en) Dosage regime of fusion compounds
SG11201804384UA (en) Geometric configurations for gastric residence systems
SG11201908560SA (en) Heterocyclic compounds useful as dual atx/ca inhibitors
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201408287RA (en) Rapid specific pathogen free animal
SG11201907742YA (en) Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201806829TA (en) 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
SG11201907846VA (en) Therapeutic rna
SG11201804443UA (en) Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201408280YA (en) Anticancer treatment
SG11201408054RA (en) Pegylated oxm variants
SG11201809341PA (en) Mobile robot
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201908075UA (en) A microneedle device
SG11201804643PA (en) Indicator device
SG11201806623VA (en) Bacteria over-expressing c-di-amp and therapeutic methods
SG11201909837YA (en) Methods for treating lung disorders
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201407368VA (en) Drug for preventing and/or treating polycystic kidney disease